Cited 13 times in
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최동훈 | - |
dc.date.accessioned | 2022-09-14T01:45:38Z | - |
dc.date.available | 2022-09-14T01:45:38Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 1346-9843 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190598 | - |
dc.description.abstract | Background: There are concerns that Asian patients respond differently to some medications. This study evaluated the efficacy and safety of evolocumab among Asian vs. other subjects in the FOURIER trial, which randomized stable atherosclerosis patients to receive either evolocumab or placebo.Methods and Results:Effects of adding evolocumab vs. placebo to background statin therapy on low-density lipoprotein cholesterol (LDL-C) reductions, cardiovascular outcomes, and adverse events were compared among 27,564 participants with atherosclerotic disease, according to self-reported Asian (n=2,723) vs. other (n=24,841) races followed for a median of 2.2 years in the FOURIER trial. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. At randomization, Asians had slightly lower LDL-C (median 89 [IQR 78-104] mg/dL vs. 92 [80-109] mg/dL; P<0.001) and were much less likely to be on a high-intensity statin (33.3% vs. 73.3%; P<0.001). Evolocumab lowered LDL-C more in Asians than in others (66% vs. 58%; P<0.001). The effect of evolocumab on the primary endpoint was similar in Asians (HR, 0.79; 95% CI, 0.61-1.03) and others (HR, 0.86; 95% CI, 0.79-0.93; P interaction=0.55). There was no excess of serious adverse events with evolocumab among Asians over others. Conclusions: Use of evolocumab robustly lowers LDL-C and is equally efficacious in lowering the risk of cardiovascular events and safe in Asians as it is in others. Trial registration: ClinicalTrials.gov NCT01764633. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Japanese | - |
dc.publisher | Japanese Circulation Society | - |
dc.relation.isPartOf | CIRCULATION JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized* / adverse effects | - |
dc.subject.MESH | Asians* | - |
dc.subject.MESH | Atherosclerosis* / drug therapy | - |
dc.subject.MESH | Atherosclerosis* / ethnology | - |
dc.subject.MESH | Cholesterol, LDL | - |
dc.subject.MESH | Heart Disease Risk Factors | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use | - |
dc.subject.MESH | PCSK9 Inhibitors* / adverse effects | - |
dc.subject.MESH | Proprotein Convertase 9 | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Anthony C Keech | - |
dc.contributor.googleauthor | Kazuma Oyama | - |
dc.contributor.googleauthor | Peter S Sever | - |
dc.contributor.googleauthor | Minao Tang | - |
dc.contributor.googleauthor | Sabina A Murphy | - |
dc.contributor.googleauthor | Atsushi Hirayama | - |
dc.contributor.googleauthor | Chen Lu | - |
dc.contributor.googleauthor | Leslie Tay | - |
dc.contributor.googleauthor | Prakash C Deedwania | - |
dc.contributor.googleauthor | Chung-Wah Siu | - |
dc.contributor.googleauthor | Armando Lira Pineda | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Min-Ji Charng | - |
dc.contributor.googleauthor | John Amerena | - |
dc.contributor.googleauthor | Wan Azman Wan Ahmad | - |
dc.contributor.googleauthor | Vijay K Chopra | - |
dc.contributor.googleauthor | Terje R Pedersen | - |
dc.contributor.googleauthor | Robert P Giugliano | - |
dc.contributor.googleauthor | Marc S Sabatine | - |
dc.identifier.doi | 10.1253/circj.CJ-20-1051 | - |
dc.contributor.localId | A04053 | - |
dc.relation.journalcode | J00534 | - |
dc.identifier.eissn | 1347-4820 | - |
dc.identifier.pmid | 33980763 | - |
dc.subject.keyword | Asians | - |
dc.subject.keyword | Evolocumab | - |
dc.subject.keyword | LDL cholesterol | - |
dc.subject.keyword | PCSK9 inhibitor | - |
dc.contributor.alternativeName | Choi, Dong Hoon | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.citation.volume | 85 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2063 | - |
dc.citation.endPage | 2070 | - |
dc.identifier.bibliographicCitation | CIRCULATION JOURNAL, Vol.85(11) : 2063-2070, 2021-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.